Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
The present invention teaches anti-Trop-2 monoclonal antibodies with high affinity and able to recognize different regions of the Trop-2 molecule, and uses thereof in the treatment and diagnosis of tumors, such as for example endometrium, breast, head and neck, colon-rectum, stomach, lung, ovary, prostate, pancreas, kidney, cervix and bladder (urothelial) tumors.
1. A combination comprising at least two isolated anti-Trop-2 monoclonal antibodies chosen among anti-Trop-2 monoclonal antibodies produced by hybridoma cell lines having deposit numbers PD 08019, PD 08020 or PD 08021.
2. The combination according to claim 1 , wherein the at least two isolated anti-Trop-2 monoclonal antibodies are produced by the hybridoma cell lines having deposit numbers PD 08019, PD 08020 and PD 08021.
3. The combination according to claim 1 , wherein the at least two isolated anti-Trop-2 monoclonal antibodies are produced by the hybridoma cell lines having deposit numbers PD 08019 and PD 08020.
4. The combination according to claim 1 , wherein the at least two isolated anti-Trop-2 monoclonal antibodies are produced by the hybridoma cell lines having deposit numbers PD 08019 and PD 08021.
5. The combination according to claim 1 , wherein the at least two isolated anti-Trop-2 monoclonal antibodies are produced by hybridoma cell lines having deposit numbers PD 08020 and PD 08021.
6. An anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08019.
7. An anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08020.
8. An anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08021.
9. A pharmaceutical composition comprising, as an active ingredient, the combination of claim 1 , an anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08019, an anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08020, or an anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08021, in association with one or more excipients and/or adjuvants that are pharmaceutically acceptable.
10. The pharmaceutical composition according to claim 9 in a form acceptable for intraperitoneal, intrapleural, intravesical, intralesion administration or administration through the hepatic artery.
11. A medicament for prevention or treatment of a tumor expressing Trop-2, the medicament comprising the combination of claim 1 , an anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08019, an anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08020, or an anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08021.
12. A medicament for prevention or treatment of Trop-2 expressing tumor metastases, the medicament comprising the combination of claim 1 , an anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08019, an anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08020, or an anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08021.
13. A method for in vitro diagnosis of a tumor expressing Trop-2, the method comprising contacting a sample with the combination of claim 1 , an anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08019, an anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08020, or an anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08021.
14. A kit for the in vitro diagnosis of a tumor expressing Trop-2, the kit comprising the combination of claim 1 , an anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08019, an anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08020, or an anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08021.
15. A method for treating or preventing a tumor expressing Trop-2 in an individual, the method comprising
administering to the individual an effective amount of the combination of claim 1 , an anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08019, an anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08020, or an anti-Trop-2 monoclonal antibody produced by hybridoma cell line having deposit number PD 08021.